All articles by Fiona Barry

Fiona Barry

CMO Moves: Regulatory catalysts for drug manufacturing-October

Pharmaceutical Technology analyses recent regulatory decisions and trial results that are expected to impact therapy manufacturing plans.

CMO Moves: Regulatory catalysts for drug manufacturing-September

Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.

CMO Moves: Regulatory catalysts for drug manufacturing—August

Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.

California’s low-cost insulin plans receive $100m manufacturing boost

Governor Newsom unveils plans to work with a CMO to produce low-cost insulin, even though most insulin is currently produced in-house by big pharma.

CMO Moves: Regulatory catalysts for drug manufacturing-July

Pharmaceutical Technology does a roundup of regulatory decisions from late April to early May that impact drugs and the CMOs enlisted to manufacture them.

CMO Moves: Regulatory catalysts for drug manufacturing-March

Pharmaceutical Technology does a roundup of regulatory decisions in recent months that impact drugs and the CMOs enlisted to manufacture them.

Supply chain report: make CMO agreements public, but ‘glib’ onshoring not the answer

A new report commissioned by the US Congress recommends that the FDA should make drug supply chain information public.

Supersized Asia and Africa deal to make Merck pill but Covid drug shortage persists

A total of 27 CMOs have agreed to produce Merck’s molnupiravir for 105 countries in Africa, Asia and the Middle East.

Russia sanctions: what next for Sputnik Covid-19 vaccine production around the world?

The Russian invasion of Ukraine has knock-on effects on the Covid-19 pandemic as supplies of Sputnik V vaccine to Asian, African, and South American countries are now in question.